Pricing Log in Create free account
Friday 6 November 2026 Export AMRX’s income statement to Excel — free account

AMNEAL PHARMACEUTICALS, INC.

AMRX Healthcare Drug Manufacturers Specialty & Generic

AMNEAL PHARMACEUTICALS, INC.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 billion, up 8.05% from fiscal 2024.

Revenue
+9.96%
EPS
+267.0%
Free cash flow
−50.9%
Total debt
+23.8%

Quarter to September 2026, against a year earlier

19.41 0.54 −2.71%
Market cap
$6.8B
P/E
36.9×
Fwd P/E
44.2×
Dividend yield
—
F-score
7/9
Altman Z
1.94
Beneish M
−2.68
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

AMNEAL PHARMACEUTICALS, INC. (AMRX) SEC filings, changes and red flags

Red flags

No red flags have been raised by AMNEAL PHARMACEUTICALS, INC.’s filings on file.

Filings

Form Period Filed What it reports Flags
8-K Nov 3, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K/A Aug 10, 2026 9.01 Financial statements and exhibits
8-K Aug 10, 2026 1.01 Entry into a material definitive agreement; 2.01 Completion of an acquisition or disposition; 2.03 Creation of a direct financial obligation; 3.02 Unregistered sales of equity securities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2026
8-K Aug 3, 2026 1.01 Entry into a material definitive agreement
8-K Jul 31, 2026 5.07 Submission of matters to a vote of security holders
8-K Jul 30, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Mar 31, 2026
8-K May 6, 2026 5.07 Submission of matters to a vote of security holders
8-K May 7, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Apr 22, 2026 1.01 Entry into a material definitive agreement; 2.02 Results of operations and financial condition; 3.02 Unregistered sales of equity securities; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2025
8-K Feb 27, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Feb 2, 2026 1.01 Entry into a material definitive agreement; 2.03 Creation of a direct financial obligation
8-K Jan 23, 2026 8.01 Other events
8-K Jan 13, 2026 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
10-Q Sep 30, 2025
8-K Oct 30, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-Q Jun 30, 2025
8-K Aug 5, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jul 16, 2025 2.02 Results of operations and financial condition; 5.02 Departure or appointment of directors or officers; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 2, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
10-K Dec 31, 2024
8-K Feb 28, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 15, 2025 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
8-K Sep 30, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Aug 7, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K May 3, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Mar 1, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits
8-K Jan 10, 2024 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure
8-K Nov 7, 2023 2.02 Results of operations and financial condition; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.